A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

To join this study, you must be between 18 and 68 years old and have been diagnosed with chronic kidney disease where you have persistent protein in your urine. You would also need to have specific changes in your APOL1 gene (known as the high-risk gene type) that are linked to this kind of kidney disease.

However, there are some reasons why you might not be able to participate. For example, if you've had an organ or bone marrow transplant, or if you've been treated for cancer in the last two years (with some exceptions like certain skin or early-stage cervical/prostate cancers). We also couldn't include you if you have Type 1 diabetes, or if you're pregnant or breastfeeding.

Additionally, conditions that might affect how your body absorbs medication, such as certain types of stomach surgery, would prevent you from taking part. The study team will review all specific medical history to ensure it's safe and appropriate for you to join.

If you decide to take part in this study, you will be given the study medication, MZE829. You will have regular visits to the clinic, where the study team will monitor your health closely. These visits will involve blood tests, urine tests, and other checks to see how your kidneys are doing and how you are responding to the medication. The team will also ask about any side effects you might be experiencing. We will explain how often these visits are, but generally research studies involve more frequent check-ups than routine care. The total duration of your participation in the study, including all visits and follow-ups, will be clearly explained to you before you make any decisions.